Follow the money
Home Committee Clinical Trials Scare Tactics Lawmakers Reuters Bill Gates CDC

 

Trust?

How confident can we be when we learn the government is so intimate with pharmaceutical companies? Do they really watch out for our children’s best interest? No individual who stands to gain financially should be on this committee.  When you wonder how the rotavirus made its way into our babies, refer to the prior pages statements.  When you wonder how thimerosal and Aluminum containing vaccines are administered to our children, refer to the prior page's statements.  If  you wonder who is minding the public health as the FDA allows drug companies to produce vaccines grown on animal tissue cultures, when they are not sure if this practice is facilitating cross species transfer of animal viruses into man, please refer to the prior page's statements.

There are huge amounts of money being made by these people who no longer worry about the consequences of their inadequate clinical trials or substandard products.  In fact, today the FDA cannot even tell health scientists the truth about vaccine contaminants and their likely effects.  The agency is bound and gagged by proprietary laws and non-disclosure agreements forced upon them by the pharmaceutical industry.

"The drug industry is stealing from us twice," said Frank Clemente, director of Public citizens Congress Watch. "First it claims that it needs huge profits to develop new drugs, even while drug companies get hefty taxpayer subsidies. Second, the companies gouge taxpayers while spending millions from their profits to buy access to lawmakers and defeat pro-consumer prescription-drug legislation.  Drug makers spent $262 million during the 1999-2000 election, which includes $177 million on lobbying, $65 million on issue ads and $20 million on campaign contributions.”

The federal affairs staff at PhRMA has quadrupled, to 20 employees today from 5 in 1999. The organization plans to spend $5 million for outside lobbyists at the federal level. In their campaign contributions, drug companies have favored Republican candidates. But PhRMA has retained a diverse group of lobbyists to ensure access to politicians of both parties.

Its Democratic lobbyists, listed in recent reports to Congress, include former Representative Vic Fazio of California; David W. Beier, who was chief domestic policy adviser to Vice President Al Gore; Joel P. Johnson, who was a top aide to President Bill Clinton and to Senator Tom Daschle, the minority leader; and Nick Littlefield, former chief counsel for Senator Edward M. Kennedy of Massachusetts.

 

 

Republicans who reported lobbying for PhRMA include former Representatives Vin Weber of Minnesota and Bill Paxon of New York; Dave Larson, former health policy adviser to Bill Frist, now the Senate majority leader; Edwin A. Buckham, former chief of staff to Tom DeLay, now the House majority leader; and Scott Hatch, the son of Senator Hatch.

 

For a list of all the government/pharma  ties go to http://www.opensecrets.org/

 

There are also news organizations with strong ties to pharmaceutical companies. Is it any wonder we never get the truth about the dangers of vaccines?
Reuters

 

Take a look at how Bill Gates makes money by supposedly helping fight disease through vaccination.

Profits

money.gif (3922 bytes)Four doses of Pneumococcal Conjugate for each child costs $242.00 approximately seven million children are targeted to receive this vaccine in the U.S. alone. It is also being advertised on television to insure more sales. This will also test public opinion for the upcoming American Academy of Pediatrics recommendation of the Prevnar vaccine, and the subsequent requirement by the CDC. According to the news agency Reuters, this is expected to deliver sales of $300 to $500 million a year for Wyeth-Lederle vaccines.  One annual report I found was from Smithkline Beecham with annual sales of $278 million for Hepatitis Vaccines and Merck with annual sales of $860 million with vaccine biologics. The promotion of vaccines is a 30 Billion dollar industry.  Just found this:GlaxoSmithKline Operating and financial review and prospects

Page 26